Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on TELA Bio (NASDAQ:TELA) but lowers the price target from $10 to $8.

August 13, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on TELA Bio but lowers the price target from $10 to $8.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100